Entyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFalpha-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease Patients in Comparative Effectiveness Real-World Data Analysis

Osaka, Japan (ots/PRNewswire) -

New clinical study also provides data for Entyvio® in inducing
complete mucosal healing and endoscopic remission, particularly in
bio-naïve patients

Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today
announced new real-world data evaluating the comparative
effectiveness of Entyvio® (vedolizumab) and tumor necrosis
factor-alpha (TNF?)-antagonist therapy in patients with moderately to
severely active ulcerative colitis (UC) or Crohn's disease (CD).
These data were presented as oral presentations at the 13th Congress
of the European Crohn's and Colitis Organization (ECCO) from February
14 to 17, 2018 in Vienna, Austria. These analyses observed that
patients with UC treated with Entyvio compared to TNF?-antagonist
therapy had statistically significant higher 12-month cumulative
rates of mucosal healing (50% vs 42%, hazard ratio [HR] 1.73, 95%
confidence interval [CI] 1.10-2.73) and clinical remission (54% vs
37%; HR 1.54, 95% CI 1.08-2.18), and numerically higher steroid-free
clinical remission rates (49% vs 38%; HR 1.43, 95% CI 0.79-2.60). In
CD, results reported statistically significant higher 12-month
cumulative rates of mucosal healing (50% vs 41%; HR 1.67, 95% CI
1.13-2.47), and numerically higher rates of clinical remission (38%
vs 34%; HR 1.27, 95% CI 0.91-1.78) and steroid-free clinical
remission (26% vs 18%; HR 1.75, 95% CI 0.90-3.43) compared to
TNF?-antagonist therapy. These analyses were conducted by the VICTORY
(Vedolizumab Health OuTComes in InflammatORY Bowel Diseases)
Consortium.[1],[2]

"These data from the VICTORY Consortium highlight the
effectiveness of Entyvio in achieving mucosal healing and clinical
remission in the real-world, and support the use of Entyvio as a
first-line biologic therapy," said Professor William Sandborn, M.D.,
Chief, Division of Gastroenterology, University of California San
Diego. "While additional research is needed to confirm these
findings, these are important comparative effectiveness analyses of
real-world data involving Entyvio and TNF?-antagonist therapy, which
further aid our understanding of biologic therapy in clinical
practice."

Of the 646 UC and 1,122 CD VICTORY Consortium patients, data from
334 UC (n=167 Entyvio patients; 49% male; median age 36 years) and
538 CD (n=269 Entyvio patients; 44% male; median age 35 years) were
analyzed. Entyvio patients were matched (1:1)* to patients on
anti-TNF? therapy using propensity scores to control for baseline
differences between groups. Researchers used Cox proportional hazard